Key result
CIN-102 avoids clinically meaningful QTcF prolongation with a maximum increase of ~4 ms vs placebo.
Why the study?
To evaluate the effects of CIN-102, a deuterated form of domperidone in development for gastroparesis, on cardiac repolarization.
Does single-dose CIN-102 (deuterated domperidone) safely preserve cardiac repolarization (QT interval) without significant prolongation in healthy volunteers?
RCT (n=62)
Double-blind (open-label for positive control)
Randomized (4-period crossover)
No
Does single-dose CIN-102 (deuterated domperidone) safely preserve cardiac repolarization (QT interval) without significant prolongation in healthy volunteers?
CIN-102 (deuterated domperidone) administered at therapeutic and supratherapeutic doses does not cause clinically meaningful QT interval prolongation in healthy volunteers, demonstrating an improved cardiac safety profile compared to the traditional formulation.
Answers are grounded in this paper and cite their sources.
Supports CIN-102 advancement without routine QT monitoring; extends cardiac safety data for deuterated domperidone in healthy volunteers.
CIN-102 is a deuterated form of domperidone in development for the treatment of acute, recurrent gastroparesis. This thorough QT study assessed the effects of CIN-102 on cardiac repolarization in 62 healthy volunteers. In this 4-period randomized crossover study, participants were administered single doses of 30-mg CIN-102 (representing therapeutic exposures), 100-mg CIN-102 (representing supratherapeutic exposures), placebo, and moxifloxacin (positive control). Continuous 12-lead electrocardiograms (ECGs) and time-matched blood samples were collected to determine plasma levels of deuterated domperidone and its major metabolites. The primary endpoint was placebo-corrected change-from-baseline QTc corrected by Fridericia's formula (ΔΔQTcF). By-time-point and concentration-QTc analyses excluded an effect on ΔΔQTcF exceeding 10 ms for both doses of CIN-102 at all time points up to deuterated domperidone plasma concentrations of ≈92 ng/mL (≈6 times the therapeutic steady-state concentration). There were no clinically relevant effects of CIN-102 on heart rate or cardiac conduction, and no deaths or serious adverse events occurred. This thorough QT study demonstrated that at doses producing therapeutic and supratherapeutic exposures, CIN-102 does not have a clinically meaningful effect on ECG parameters, including QT interval. This modified formulation of domperidone provides a potential gastroparesis treatment while decreasing the risk of QT prolongation associated with the traditional formulation of domperidone.
No takes yet. Share an insight, caveat, or question.
Bond et al. (2026) conducted an RCT in Healthy volunteers (n=62). CIN-102 (deuterated domperidone) vs. Placebo was evaluated on Placebo-corrected change from baseline QTcF (ΔΔQTcF) (MD 3.7 ms, 95% CI 1.95-5.41). CIN-102 did not clinically prolong the QT interval at therapeutic or supratherapeutic doses, showing a maximum placebo-corrected change from baseline QTcF of 3.7 ms, below the 10 ms threshold.
Synapse has enriched 10 related papers. Consider them for comparative context: